Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation

被引:65
作者
Calvo, F. A.
Serrano, F. J.
Diaz-Gonzalez, J. A.
Gomez-Espi, M.
Lozano, E.
Garcia, R.
de la Mata, D.
Arranz, J. A.
Garcia-Alfonso, P.
Perez-Manga, G.
Alvarez, E.
机构
[1] Hosp Gen Univ Gregorio Maranon, Dept Oncol, Madrid 28007, Spain
[2] Hosp Gen Univ Gregorio Maranon, Radiat Oncol Serv, Madrid 28007, Spain
[3] Hosp Gen Univ Gregorio Maranon, Dept Pathol, Madrid 28007, Spain
关键词
neoadjuvant oxaliplatin; chemoradiation; tegafur; rectal cancer; downstaging;
D O I
10.1093/annonc/mdl085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare efficacy in terms of pathologic response in LARC patients treated with preoperative chemoradiation, with or without a short-intense course of induction oxaliplatin. Patients and Methods: From 05/98 to 10/02, 114 patients were treated with preoperative chemoradiation (4500-5040 cGy + oral Tegafur 1200 mg/day) for cT(3)-4N+/xM0 rectal cancer. Starting 05/01, 52 consecutive patients additionally received induction FOLFOX-4, oxaliplatin (85 mg/m(2) iv d1), 5-FU (400 mg/m(2) iv bolus d1) and 600 mg/m(2) iv continuous infusion in 22 h with leucovorin (200 mg iv) d1 and d2, every 15 days (2 cycles), followed by the previously described Tegafur chemoradiation regime. Surgery was performed in 5-6 weeks. Pathological assessment investigated post-treatment T and N status in the rectal wall and peri-rectal tissues. Results: Patients, tumor and treatment characteristics were comparable between groups. Incidence of pT(0) specimens was significantly increased by induction FOLFOX-4 (P = 0.006). Total T and N downstaging were 58% versus 75% and 42% versus 40%, respectively (P = ns). T downstaging of >= 2 categories was significantly superior in FOLFOX-4 group (P = 0.029). Conclusions: Short-intense induction FOLFOX-4 significantly improves pathologic complete response in LARC patients treated with tegafur-sensitized preoperative chemoradiation. The 44% rate of pT(0)-(1) specimens observed in the oxaliplatin group should impulse innovative surgical approaches to promote ano-rectal sphincter conserving protocols.
引用
收藏
页码:1103 / 1110
页数:8
相关论文
共 58 条
[41]   Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study [J].
Machiels, JP ;
Duck, L ;
Honhon, B ;
Coster, B ;
Coche, JC ;
Scalliet, P ;
Humblet, Y ;
Aydin, S ;
Kerger, J ;
Remouchamps, V ;
Canon, JL ;
Van Maele, P ;
Gilbeau, L ;
Laurent, S ;
Kirkove, C ;
Octave-Prignot, M ;
Baurain, JF ;
Kartheuser, A ;
Sempoux, C .
ANNALS OF ONCOLOGY, 2005, 16 (12) :1898-1905
[42]  
MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO
[43]  
2-C
[44]   No downstaging after short-term preoperative radiotherapy in rectal cancer patients [J].
Marijnen, CAM ;
Nagtegaal, ID ;
Kranenbarg, EK ;
Hermans, J ;
van de Velde, CJH ;
Leer, JWH ;
van Krieken, JHJM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1976-1984
[45]   Oxaliplatin-based combined-modality therapy for rectal cancer [J].
Minsky, BD .
SEMINARS IN ONCOLOGY, 2003, 30 (04) :26-33
[46]   Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer [J].
Nagtegaal, ID ;
Marijnen, CAM ;
Kranenbarg, EK ;
Mulder-Stapel, A ;
Hermans, J ;
van de Velde, CJH ;
van Krieken, JHJM .
JOURNAL OF PATHOLOGY, 2002, 197 (01) :20-27
[47]   The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer [J].
Nakfoor, BM ;
Willett, CG ;
Shellito, PC ;
Kaufman, DS ;
Daly, WJ .
ANNALS OF SURGERY, 1998, 228 (02) :194-200
[48]  
Pahlman L, 1997, NEW ENGL J MED, V336, P980
[49]  
Reerink O, 2005, ANTICANCER RES, V25, P629
[50]   Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer [J].
Rödel, C ;
Martus, P ;
Papadoupolos, T ;
Füzesi, L ;
Klimpfinger, M ;
Fietkau, R ;
Liersch, T ;
Hohenberger, W ;
Raab, R ;
Sauer, R ;
Wittekind, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8688-8696